title: Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice.
abstract: BACKGROUND
  The dopamine transporter (DAT) is thought to play a major role in the rewarding effects of cocaine. Therefore, it is surprising that cocaine reveals conditioned effects in DAT knockout (DAT-KO) mice.
  
  
  OBJECTIVE
  To examine these findings further, we obtained complete dose-effect curves for DAT-KO and DAT wild-type (DAT-WT) mice in a cocaine conditioned place preference (CPP) procedure.
  
  
  METHODS
  Congenic C57BL6 background female DAT-KO and DAT-WT mice were conditioned in a three-compartment place preference apparatus. Conditioning consisted of three 30-min sessions with cocaine (2.5, 5.0, 10.0, 20.0, or 40.0 mg/kg) and three 30-min sessions with saline. The distribution of time in each choice compartment was determined after each pair of conditioning sessions (one cocaine and one saline session).
  
  
  RESULTS
  DAT-WT mice revealed CPP over a wide range of cocaine doses (5.0-40 mg/kg), whereas DAT-KO mice revealed CPP over a more restricted range of doses, with consistent CPP only occurring with 10 mg/kg of cocaine.
  
  
  CONCLUSIONS
  CPP for cocaine develops in both DAT-KO and DAT-WT mice; however, the dose range at which CPP develops is much more restricted in DAT-KO mice than in DAT-WT mice. These observations corroborate the significant role of DAT inhibition in cocaine's conditioned effects.
authors.affiliation: Department of Cell Biology, Duke University Medical Center, Durham, NC 27710, USA. i.medvedev@cellbio.duke.edu
authors.forename: Ivan O
authors.initials: IO
authors.lastname: Medvedev
authors.forename: Raul R
authors.initials: RR
authors.lastname: Gainetdinov
authors.forename: Tatyana D
authors.initials: TD
authors.lastname: Sotnikova
authors.forename: Laura M
authors.initials: LM
authors.lastname: Bohn
authors.forename: Marc G
authors.initials: MG
authors.lastname: Caron
authors.forename: Linda A
authors.initials: LA
authors.lastname: Dykstra
mesh_terms: D000818:Animals; D003042:Cocaine / Q000008:administration & dosage / Q000494:pharmacology*; D003216:Conditioning, Operant / Q000187:drug effects* / Q000502:physiology; D050483:Dopamine Plasma Membrane Transport Proteins / Q000235:genetics / Q000502:physiology*; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D007274:Injections, Intraperitoneal; D051379:Mice; D020297:Mice, Congenic; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D013997:Time Factors
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; D003042:Cocaine
references.citation: Prog Neurobiol. 1998 Dec;56(6):613-72
references.pmid: 9871940
references.citation: Life Sci. 1998;62(17-18):1573-5
references.pmid: 9585138
references.citation: Trends Pharmacol Sci. 2002 Aug;23(8):367-73
references.pmid: 12377578
references.citation: Science. 1999 Jan 15;283(5400):397-401
references.pmid: 9888856
references.citation: Brain Res. 2003 Apr 25;970(1-2):214-20
references.pmid: 12706263
references.citation: Annu Rev Pharmacol Toxicol. 2003;43:261-84
references.pmid: 12359863
references.citation: Nature. 1997 Apr 24;386(6627):827-30
references.pmid: 9126740
references.citation: Nat Neurosci. 1998 Jun;1(2):132-7
references.pmid: 10195128
references.citation: Science. 1987 Sep 4;237(4819):1219-23
references.pmid: 2820058
references.citation: Neuron. 2002 Oct 10;36(2):213-28
references.pmid: 12383778
references.citation: Behav Pharmacol. 2000 Jun;11(3-4):279-90
references.pmid: 11103882
references.citation: Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4029-34
references.pmid: 9520487
references.citation: Nature. 2003 Apr 10;422(6932):614-8
references.pmid: 12687000
references.citation: Nature. 1996 Feb 15;379(6566):606-12
references.pmid: 8628395
references.citation: Psychopharmacology (Berl). 1999 Sep 1;146(1):73-80
references.pmid: 10485967
references.citation: Nature. 2001 Jul 5;412(6842):43-8
references.pmid: 11452299
references.citation: J Neurosci. 2001 May 1;21(9):RC141: 1-4
references.pmid: 11312315
references.citation: Drug Alcohol Depend. 1998 Jun-Jul;51(1-2):13-22
references.pmid: 9716927
references.citation: J Neurosci. 2002 May 15;22(10):RC222
references.pmid: 12006604
references.citation: Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):372-7
references.pmid: 14691264
references.citation: J Pharmacol Exp Ther. 2000 Apr;293(1):121-7
references.pmid: 10734161
references.citation: Psychopharmacology (Berl). 1999 Jan;141(2):118-22
references.pmid: 9952035
references.citation: Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7699-704
references.pmid: 9636213
references.citation: J Neurosci. 2003 Nov 12;23 (32):10265-73
references.pmid: 14614085
references.citation: Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
references.pmid: 2899326
references.citation: Neurosci Biobehav Rev. 1995 Spring;19(1):39-51
references.pmid: 7770196
references.citation: Psychopharmacology (Berl). 1999 May;144(1):77-82
references.pmid: 10379627
references.citation: J Neurosci. 2001 Jan 1;21(1):305-13
references.pmid: 11150348
references.citation: Neuroreport. 2001 Aug 8;12(11):2549-52
references.pmid: 11496146
references.citation: Brain Res. 1998 Aug 10;801(1-2):67-71
references.pmid: 9729284
references.citation: Eur J Neurosci. 2002 Aug;16(3):514-20
references.pmid: 12193195
references.citation: J Neurosci. 2004 Feb 11;24(6):1265-71
references.pmid: 14960596
references.citation: Nat Neurosci. 1998 Aug;1(4):304-9
references.pmid: 10195164
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5300-5
references.pmid: 11320258